10. Systemic MMF versus systemic CsA: adverse effects.

Study ID and comparisons	Side effects	Number of events/number followed up in the experimental group	Number of events/number followed up in the control group	OR (95% CI)
Reinhard 2001 Systemic MMF versus systemic CsA	Hepatotoxicity	2/29	3/27	0.6 (0.10 to 3.72)
	Arterial hypertension	0/29	3/27	0.12 (0.01 to 1.17)
	Gingiva problems	0/29	3/27	0.12 (0.01 to 1.17)
	Neurovegetative disorders	0/29	3/27	0.12 (0.01 to 1.17)
	Hodgkin's lymphoma	0/29	1/27	0.13 (0.00 to 6.35)
	Recurrence of acoustic neurinoma	1/29	0/27	6.90 (0.14 to 348.44)
	Exacerbation of atopic dermatitis	1/29	0/27	6.90 (0.14 to 348.44)

MMF: mycophenolate mofetil
 CsA: cyclosporine A
 OR: odds ratio
 CI: confidence interval